<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Erythromycin (topical): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Erythromycin (topical): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Erythromycin (topical): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9119" href="/d/html/9119.html" rel="external">see "Erythromycin (topical): Drug information"</a> and <a class="drug drug_patient" data-topicid="11673" href="/d/html/11673.html" rel="external">see "Erythromycin (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8086237"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Ery;</li>
<li>Erygel</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10484228"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Macrolide</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Topical</span></li></ul></div>
<div class="block dop drugH1Div" id="F8086395"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Akne-Mycin ointment has been discontinued in the US for more than 1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225'])">Ref</a></span>):<b> Note: </b>Due to emerging resistance patterns, should not typically be used as monotherapy for the management of acne vulgaris (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225','lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225','lexi-content-ref-26897386'])">Ref</a></span>). Children ≥7 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: Apply as a thin film over the affected area once or twice daily. Therapeutic response may take several weeks (up to 6 to 8 weeks); discontinue use if no improvement after 6 to 8 weeks or if condition worsens</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment, solution: Apply over the affected area twice daily (morning and evening); drying and peeling may be controlled by reducing frequency of application</p>
<p style="text-indent:-2em;margin-left:4em;">Pads (pledgets): Rub pad over affected area twice daily (morning and evening); additional pads may be used if needed</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51108712"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51108713"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F8086396"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9119" href="/d/html/9119.html" rel="external">see "Erythromycin (topical): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Reserve for patients who cannot use first-line agents. Use in combination with benzoyl peroxide to reduce the risk for the development of antibiotic resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-Graber.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-Graber.1'])">Ref</a></span>). Therapeutic response may take up to 6 to 8 weeks; discontinue use if no improvement after 6 to 8 weeks or if condition worsens.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Gel: Apply sparingly as a thin film over the affected area once or twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Ointment, solution: Apply to affected area twice daily (morning and evening); drying and peeling may be controlled by reducing the frequency of application.</p>
<p style="text-indent:-2em;margin-left:6em;">Pads: Rub pad over affected areas twice daily (morning and evening); additional pads may be used, if needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Erysol [Canadian product]: Apply thin film to affected area twice daily (morning and evening after the skin has been thoroughly washed and patted dry); may decrease to once daily if irritation develops at application site. Maximum therapy duration: 3 months.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991821"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989100"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F8086294"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Desquamation, erythema, exfoliation of skin, oily skin, pruritus, rough skin (leather appearance), skin fissure (around mouth), skin tenderness, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Application site irritation (includes local dryness, localized burning, localized erythema, localized tenderness, stinging of the skin)</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Eye irritation</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Abdominal distress, abdominal pain, diarrhea, facial edema, hypersensitivity reaction, skin rash</p></div>
<div class="block coi drugH1Div" id="F8086279"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to erythromycin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F20302595"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Discontinue if significant diarrhea, abdominal cramps, or passage of blood and mucus occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Concurrent topical acne therapy: Use with caution especially with peeling, desquamating or abrasive agents; irritation may be cumulative. Discontinue use if irritation or dermatitis occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Topical gel: May be flammable. Keep away from heat and flame.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For topical use only; not for ophthalmic use. Avoid contact with eyes, nose, mouth, mucous membranes, or broken skin. Lack of improvement or worsening of acne may indicate microbial resistance. Alternative therapy may be required for severe acne (eg, nodular). Consider alternate therapy in patients with poor tolerance to macrolides or clindamycin. In the treatment of acne, American Academy of Dermatology acne guidelines recommend erythromycin (topical) be used in conjunction with other therapies (<i>not</i> as monotherapy) due to the risk of bacterial resistance. If given for mild acne, erythromycin (topical) should be used in combination with benzoyl peroxide. If given for moderate to severe acne, it should be used in combination with a topical retinoid or systemic antibiotic agent (AAD [Zaenglein 2016]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878768"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F8086447"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erygel: 2% (30 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (30 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Pad, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ery: 2% (60 ea) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2% (60 mL)</p></div>
<div class="block geq drugH1Div" id="F8086240"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8086450"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Erygel External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $6.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Erythromycin External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per gram): $2.02 - $5.48</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Erythromycin External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2% (per mL): $0.83</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614436"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Topical: Prior to treatment, thoroughly wash affected area with mild soap and warm water, rinse, and pat dry. Wash hands after use. Avoid contact with the eyes, nose, mouth and other mucous membranes, and broken skin.</p>
<p style="text-indent:-2em;margin-left:2em;">Pads: Discard pad after single use; keep container tightly closed between uses.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution: Use applicator tip to apply solution.</p></div>
<div class="block adm drugH1Div" id="F20302640"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Topical: Prior to treatment, thoroughly wash affected area with mild soap and warm water, rinse, and pat dry. Discard pad after single use. Wash hands after use. Avoid contact with the eyes, nose, mouth and other mucous membranes, and broken skin.</p></div>
<div class="block sts drugH1Div" id="F8086331"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Ery: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Erygel: Store at 20°C to 25°C (68°F to 77°F). Protect from heat and flame.</p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin solution: Store at 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Erysol [Canadian product]: Store at 15°C to 30°C (59°F to 86°F). Protect from heat and flame.</p></div>
<div class="block usep drugH1Div" id="F53570819"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of acne vulgaris (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F8085307"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Erythromycin may be confused with azithromycin, clarithromycin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299282"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8086299"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Topical): Erythromycin (Topical) may diminish the therapeutic effect of Clindamycin (Topical).  Management: Consider avoiding use of topical erythromycin and topical clindamycin at the same application site when treating acne vulgaris. This recommendation does not appear to apply to intravaginal use of clindamycin for the treatment of bacterial vaginosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ISOtretinoin (Topical): May enhance the adverse/toxic effect of Erythromycin (Topical).<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F9793457"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">The amount of erythromycin available systemically following topical application is considered to be very low (Akhavan 2003). Systemic absorption would be required in order for erythromycin to cross the placenta and reach the fetus.</p>
<p style="text-indent:0em;margin-top:2em;">Topical erythromycin may be used for the treatment of acne in pregnancy (AAD [Zaenglein 2016]; Eichenfield 2013).</p></div>
<div class="block pha drugH1Div" id="F8089427"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Antibacterial activity is due to inhibition of RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation. Alcohol component induces skin drying and peeling.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12707703"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Aknemycin | Eryacne | Eryderm | Stiemycin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ambamida | Atlamicin | Eri acne | Erisol | Eritroderm | Eryacne | Eryfluid | Iloticina | Kitacne | Lederpax | Pentoclave | Stiemycin | Toperit | Trixne</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Akne Cordes | Eryaknen | Meromycin | Stiemycine</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Eryacne</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Acneryne | Aknemycin | Erycine | Eryderm | Inderm | Stimycine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Davercin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Eryacnen | Ilosone | Pantomicina topica | Stiemycin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Eryaknen | Eryderm | Inderm | Staticin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Erysept</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Eryacnen Gel | Gelerit</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bonac | Eryacne | Ilosone | Iloticina | Iloticina plus | Pantomicina | Stiemycin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aknefug el | Aknemycin | Clinofug | Eryfluid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Akne Cordes | Aknederm ery | Aknefug el | Aknemycin | Aknin | Clinofug | Eryaknen | Erydermec | Erytop stada | Hydrodermed | Infectomycin | Sanasepton | Skid e | Stiemycine</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Emina | Eryacnen | Eryderm | Inderm | Pantomicina | Stiemycin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Eryacne | Erysol | Inderm | T-Stat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Aknefug el | Erythromycine bailleul | Ilosone | Inderm</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acni Care | Aknemycin | Eryderm | Erythrin | Erytin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Deripil | Eridosis | Euskin | Lederpax | Loderm | Pantodrin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ery-max</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eryacne | Eryfluid | Erythrocine | Erythrogel b | Erythromycine bailleul</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eryacne | Stiemycin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Acne hermal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Akne mycin | Eryacne | Stiemycin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Aknefug-el | Aknemycin | Meromycin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aknemycin | Eryderm | Erymed</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Stiemycin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Acnetrim</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acnesol | Acnicin | Althrocin | Eromed | Eryacne | Erylent | Erythrotone | Erytop | Rakcen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eritromicina | Eryacne</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aknemycin | Philamycin | Stiemycin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Spotex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Akne mycin | Amone | Eighteen | Eryacne | Erymax | Erysol | Erythro | Inderm | Stiemycin | Swabcin | Ye green | Yegreen</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Eryderm | Stiemycin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Erycine | Eryderm | Eryfluid | Erythromycine | Med erythromycin | Spotex | Stiemycine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Aknefug el | Erydermec</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Acneryne | Eryderm | Erythromycine | Inderm | Monomycin | Stiemycine | Stimycine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aknefug el | Clinofug</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Eryacne | Eryfluid | Erysol | Stimycine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Eryacnen | Eryderm | Lederpax | Sansacne | Stiemycin | T-Stat</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Aknemycin | Eryderm</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Akne mycin | Aknemycin | Eryacne | Inderm | Stiemycin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Eryacne | Stiemycin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bonac | Eryacnen | Erysol | Ilosone st | Inderm</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Sansacne | Stiemycin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Eryderm | Ethrox</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aknemycin | Davercin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">A/T/S | Akne mycin | Del mycin | E solve | Emgel | Ery | Erycette | Eryderm | Erygel | Erythra-derm | Ilosone | Staticin | T-Stat | Theramycin z</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Clinac</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Stiemycin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Eryfluid | Inderm</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Eryderm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Acnetrim | Akne mycin | Eryacne | Eryderm | Stiemycin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aknefug-el | Aknemycin | Eryfluid | Inderm</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Erazit | Eryacne | Stiemycin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Eryfluid | Erysol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Akela | Akela forte | Aknilox | Eritsa | Eryacne</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Acne free | Bezin | Fuye | Ilosone | Stiemycin | Winston anti acne</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Erythrokant es</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cliniderm | Erisol | Eryacne | Stiemycin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bonac | Eryacne | Iloticina | Inderm</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Ecingel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Erycette | Ilosone | Ilotycin ts | Stiemycin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Eromycin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-12814337">
<a name="12814337"></a>Akhavan A and Bershad S, "Topical Acne Drugs: Review of Clinical Properties, Systemic Exposure, and Safety," <i>Am J Clin Dermatol</i>, 2003, 4(7):473-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/12814337/pubmed" id="12814337" target="_blank">12814337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23302006">
<a name="23302006"></a>Dréno B, Layton A, Zouboulis CC, et al. Adult female acne: a new paradigm. <i>J Eur Acad Dermatol Venereol</i>. 2013;27(9):1063-1070.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/23302006/pubmed" id="23302006" target="_blank">23302006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;131 (Suppl 3):S163-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ery 2% Pads (erythromycin topical) [prescribing information]. Allegan, MI: Padagis; February 2022.</div>
</li>
<li>
<div class="reference">
                  Ery Pads (erythromycin) [prescribing information]. Allegan, MI: Perrigo; August 2011.</div>
</li>
<li>
<div class="reference">
                  Erygel (erythromycin) [prescribing information]. Newtown, PA: Prestium Pharma; June 2018.</div>
</li>
<li>
<div class="reference">
                  Erythromycin [prescribing information]. Basking Ridge, NJ: Micro Labs USA Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12833004">
<a name="12833004"></a>Gollnick H, Cunliffe W, Berson D, et al, "Management of Acne: A Report From a Global Alliance to Improve Outcomes in Acne," <i>J Am Acad Dermatol</i>, 2003, 49(1 Suppl):S1-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/12833004/pubmed" id="12833004" target="_blank">12833004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.1">
<a name="Graber.1"></a>Graber E. Acne vulgaris: overview of management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed March 3, 2022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/erythromycin-topical-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15978 Version 218.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
